Tradestie Institutional Equity Comparison Engine

RXRX vs PVLA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PVLA Overall Edge

PVLA Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Palvella Therapeutics, Inc. Common Stock (PVLA) driven by superior Momentum & Technical, Options & Structure while RXRX counters with relative strength in Growth & Margin. Fundamentally, RXRX trades at N/M Forward P/E with -734.2% operating margin (+258.5% YoY revenue) versus PVLA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, RXRX sits in BREAKDOWN (61st %ile IV; Dealer Gamma Walls on Pro) against PVLA sits in CONSOLIDATION (2nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
RXRX N/M vs PVLA N/M Fwd P/E
Growth & Margin Winner RXRX
Op Margin -734.2% vs 0.0% ยท YoY +258.5% vs +0.0%
Momentum & Technical Winner PVLA
1Y -32.9% vs +80.2% ยท 52W Pos 6% vs 68%
Options & Structure Winner PVLA
BREAKDOWN (61st %ile IV) vs CONSOLIDATION (2nd %ile IV)
RXRX NASDAQ
Recursion Pharmaceuticals, Inc. Class A Common Stock
Biological Products, (No Disgnostic Substances)
$2.90
-8.79% 1D
Market Cap $2.1B
1M Return -16.16%
1Y Return -32.91%
Forward P/E N/M
Unified AI Score
49.5 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 69.0 Mom 64.0
PVLA NASDAQ
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap $2.2B
1M Return +20.56%
1Y Return +80.16%
Forward P/E N/M
Unified AI Score
48.2 / 100 HOLD
Tech 35.0 Fund 53.0 Flow 67.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RXRX -32.91% PVLA +80.16% Spread: +113.07 pp (PVLA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period RXRX Revenue PVLA Revenue RXRX Op. Margin PVLA Op. Margin Margin Edge
FY2018 N/A $30M N/A -113.1% PVLA
FY2019 $0M $40M -2692.6% -62.2% PVLA
FY2020 $0M $30M -2135.7% -115.7% PVLA
FY2021 $10M $30M -1795.8% -165.0% PVLA
FY2022 $40M $30M -616.7% -167.8% PVLA
FY2023 $40M $40M -785.3% -27.7% PVLA
FY2024 $60M N/A -814.1% N/A RXRX
FY2025 $70M N/A -867.9% N/A RXRX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RXRX (3) vs PVLA (4)
Institutional Metric RXRX PVLA Criterion Row Winner
Market Capitalization Scale $2.1B $2.2B Larger Scale PVLA
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +258.5% +0.0% Higher Growth RXRX
Operating Margin (TTM) Profitability -734.2% 0.0% Higher Margin PVLA
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -48.7% -63.4% Higher ROE RXRX
52-Week Range Position Momentum 6% ($3โ€“$5) 68% ($72โ€“$180) Stronger Trend PVLA
Beta / 30D Volatility Risk Regime 3.01ฮฒ ยท 85% Vol 1.66ฮฒ ยท 75% Vol Lower Realized Risk PVLA
Unified Institutional Score Composite Signal 49.5 / 100 (HOLD) 48.2 / 100 (HOLD) Higher Composite RXRX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RXRX vs PVLA Buy Guide
RXRX BREAKDOWN
30d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 61st %ile
IV Regime Elevated (60thโ€“80th %ile)
Live RXRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PVLA CONSOLIDATION
70d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 2nd %ile
IV Regime Compressed (<25th %ile)
Live PVLA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RXRX nor PVLA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.